Positron Emission Tomography–Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial
Journal of Clinical Oncology · 2025
DOI: 10.1200/jco-25-00439 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, 2025. Verfasst von Justin Ferdinandus und 34 weiteren Autor:innen. Beteiligte Einrichtung: Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldor…. Hauptthemen laut MEDLINE: Hodgkin Disease, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Positron emission tomography (PET)-guided therapy with 4-6 cycles of brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone (BrECADD) is highly effective in younger patients with advanced-stage classic Hodgkin lymphoma (AS-cHL). We report feasibility and efficacy of PET-guided BrECADD as first-line treatment in older patients with AS-cHL. PATIENTS AND METHODS Patients with AS-cHL aged 61-75 years were enrolled in a phase II single-arm cohort of the HD21 trial (ClinicalTrials.gov identifier: NCT02661503 ). Patients with negative PET/computed tomography after 2×BrECADD (PET2) received a total of 4×BrECADD, while PET2-positive patients received 6×BrECADD. The primary end point was the centrally reviewed complete remission (CR) rate after the end of chemotherapy (EOC). Secondary end points included feasibility, adverse events, treatment-related morbidity (TRMB), progression-free survival (PFS), overall survival (OS), and health-related quality of life (HRQoL). RESULTS Between June 2020 and April 2023, 85 patients were enrolled, of whom 83 with a median age of 67 years (range, 61-75) were analyzed in the intention-to-treat cohort. Most prevalent ≥grade 3 toxicities included leukopenia (n = 80 [96%]), thrombocytopenia (n = 71 [86%]), anemia (n = 57 [69%]), and febrile neutropenia (n = 46 [55%]). Forty-eight (60%) of 80 patients with centrally reviewed PET2 were scheduled for 4×BrECADD and 32 (40%) for 6×BrECADD. Of these, 71 patients (89%) received the target number of cycles. Sixty-eight patients (82%; 95% CI, 72 to 90) achieved CR at EOC. PFS and OS estimates at 2 years were 91.5% (95% CI, 85 to 98) and 90.8% (95% CI, 84 to 98), respectively. No death was attributed to study treatment. Initially, impaired HRQoL scores improved during follow up and on average reached population reference values. CONCLUSION PET-guided BrECADD in older patients is feasible and effective. With a PFS rate on par with that of younger patients, short duration, and limited anthracycline exposure, BrECADD is a valuable treatment option also for older patients with AS-cHL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), German Hodgkin Study Group (GHSG), University of Cologne…
- Department of Oncology, Oslo University Hospital, Oslo, Norway.
- Nordic Lymphoma Group, Arhus, Denmark.
- Department of Hematology, and Stem Cell Transplantation, West German Cancer Center and German Cancer Consortium (DKTK partner site Essen), University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
- Department of Hematology, Hanusch Krankenhaus, Vienna, Austria.
- Oncological Center, Johanniter Hospital, Bonn, Germany.
ORCID-Profile: Justin Ferdinandus, Andreas Hüttmann, Felicitas Hitz, Andrea Kerkhoff, Fernando Roncolato, Johannes C Hellmuth, Carsten Kobe, Christian Baues, Michael Fuchs, Janina Jablonski, Gundolf Schneider, Hishan Tharmaseelan, Dennis A Eichenauer, Bastian von Tresckow, Peter Borchmann, Paul J Bröckelmann
Zitieren
APA
Ferdinandus, J., Kaul, H., Fosså, A., Hüttmann, A., Keil, F., Ko, Y. D., Hitz, F., Schwarz, M., Trenker, C., Kerkhoff, A., Staib, P., Wille, K., Dresel, I., Hahn, D., Hertenstein, B., Moosmann, P., Mey, U., Balabanov, S., Armytage, T., …, & Bröckelmann, P. J. (2025). Positron Emission Tomography–Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-00439
Vancouver
Ferdinandus J, Kaul H, Fosså A, Hüttmann A, Keil F, Ko YD, et al. Positron Emission Tomography–Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial. Journal of Clinical Oncology. 2025. doi:10.1200/jco-25-00439
BibTeX
@article{Ferdinandus2025,
author = {Ferdinandus, Justin and Kaul, Helen and Fosså, Alexander and Hüttmann, Andreas and Keil, Felix and Ko, Yon-Dschun and Hitz, Felicitas and Schwarz, Michaela and Trenker, Corinna and Kerkhoff, Andrea and Staib, Peter and Wille, Kai and Dresel, Irmgard and Hahn, Dennis and Hertenstein, Bernd and Moosmann, Peter and Mey, Ulrich and Balabanov, Stefan and Armytage, Tasman and Roncolato, Fernando and Hellmuth, Johannes C and Hertzberg, Mark and Kobe, Carsten and Klapper, Wolfram and Baues, Christian and Eich, Hans-Theodor and Kreissl, Stefanie and Fuchs, Michael and Jablonski, Janina and Schneider, Gundolf and Tharmaseelan, Hishan and Eichenauer, Dennis A and von Tresckow, Bastian and Borchmann, Peter and Bröckelmann, Paul J},
title = {Positron Emission Tomography–Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial},
journal = {Journal of Clinical Oncology},
year = {2025},
doi = {10.1200/jco-25-00439}
}
EUVIMED